Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
Benzinga
NOVEMBER 7, 2022
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. NASDAQ: OYST ), ("Oyster Point Pharma"), today announced that it has entered into a definitive agreement under which Viatris Inc.
Let's personalize your content